Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, "Navigating Transition: Supporting Young Adults With Epilepsy Into Adult Care," Danielle Andrade, MD, MSc, adult neurologist at the University of Toronto and co-chair of the ILAE Transition Task Force, discussed the critical process of moving pediatric patients with epilepsy into adult care. She highlighted findings from the task force’s global survey on transition practices, revealing major differences across regions. Andrade also shared important considerations for students with epilepsy entering college, including lifestyle management and the “perfect storm” of seizure triggers like sleep deprivation, alcohol, and medication adherence. She spoke on the vital role of reproductive health discussions, the utility of readiness questionnaires, and the challenges of coordinating multi-specialty care. Finally, Andrade underscored the importance of clear communication between pediatric and adult neurologists, as well as the need for stronger guidelines and education worldwide.

Episode Breakdown:

1:00 – Global survey findings on epilepsy transition of care

2:10 – Key considerations for students with epilepsy entering college

3:50 – Ensuring continuity of care during transition into adulthood

5:45 – Neurology News Minute

7:30 – Common challenges and strategies to overcome them

9:30 – Final thoughts on back-to-school care and global survey insights

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, "Improving Quality of Life in Movement Disorders Through Nonmotor Symptom Management" Alex Dessy, MD, clinical assistant professor in movement disorders at Jefferson Health, shares a comprehensive look at modern-day care strategies for patients with Parkinson disease and other movement disorders. Dessy discusses the foundational role of detailed history-taking, exam-based observation, and phenomenology in diagnosing complex conditions, along with the growing utility of genetic and imaging tools. She also explains the challenges of managing nonmotor symptoms—like sleep disturbance, fatigue, and constipation—and how lifestyle strategies and interdisciplinary collaboration are often as vital as medication. Lastly, she emphasizes the importance of clear and compassionate communication with patients and families as neurology becomes increasingly therapeutic.

Episode Breakdown:

1:00 – How movement disorder diagnosis is approached through history, physical exam, and phenomenology

4:05 – What makes certain movement disorder cases complex and how diagnostics like genetics and imaging are used

6:20 – Neurology News Minute

8:45 – How nonmotor symptoms in Parkinson’s (fatigue, constipation, sleep) are managed with lifestyle strategies

12:30 – Approaching therapeutic communication and expectation-setting with patients and families

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, "Donanemab’s New Dosing Regimen: Lowering ARIA Risk in Alzheimer’s Care" John Sims, MD, head of medical development for donanemab at Eli Lilly and Company, joins NeurologyLive to discuss the recently updated label for donanemab (Kisulna), an anti-amyloid Alzheimer disease (AD) therapy. Sims breaks down the key safety data from the TRAILBLAZER-ALZ-6 study (NCT05738486) that led to a newly approved titration-based dosing regimen aimed at minimizing ARIA risk. He outlines considerations for clinicians treating patients with early-stage AD, including genotype-based stratification, ARIA severity patterns, and implications for prescribing and patient counseling. Furthermore, Sims also shares takeaways about donanemab’s clinical impact and how the results may shape the future of anti-amyloid therapy development and AD care.

Episode Breakdown:

1:00 – Overview of the new donanemab dosing regimen and its goal to reduce ARIA risk

2:30 – Rationale behind the four different dosing strategies tested in Trailblazer-ALZ-6

6:00 – What clinicians should know about patient risk and genotype testing

8:00 – Neurology News Minute

10:10 – Clinical implications of the updated label, including risk-benefit conversations

13:45 – Surprising results from the trial, particularly for APOE4 homozygous patients

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to this special episode of the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. For major FDA decisions in the field of neurology, we release short special episodes to offer a snapshot of the news, including the main takeaways for the clinical community, as well as highlights of the efficacy and safety profile of the agent in question.

In this special FDA-focused episode of Mind Moments, migraine expert Stewart Tepper, MD, professor of neurology at the Geisel School of Medicine at Dartmouth, discusses the recent FDA approvals of STS101 (Atzumi; Satsuma Pharmaceuticals) and CT-132 ( ) for the acute and preventive treatment of migraine. Tepper breaks down the pharmacological profile and clinical utility of DHE, the formulation behind STS101, and how the latest delivery innovations may expand its use in acute migraine care. He also dives into the approval data behind CT-132, the first-ever FDA-approved prescription digital therapeutic for migraine, and what it could mean for patients and clinicians alike. Tepper highlights the need for clinician education as novel therapeutics reshape the treatment landscape and offers insight into how these new tools could improve patient outcomes with fewer side effects and better accessibility.

For more of NeurologyLive's coverage of STS101 and CT-132 for migraine, head here: FDA Approves STS101 Nasal Powder as New Treatment for Acute Migraine

FDA Approves CT-132 as First Digital Therapeutic for Preventive Treatment of Episodic Migraine

Episode Breakdown:

1:10 – Overview of DHE, patient suitability, and STS101’s place in treatment

6:05 – Efficacy and safety data from the ASCEND and SUMMIT trials for STS101

10:20 – The expanding migraine toolbox and need for clinician education

15:10 – CT-132’s first-in-class status and clinical trial data

16:25 – Clinical use of CT-132 as an add-on preventive

19:30 – The knowledge gap on digital therapeutics and educating the neurology community

23:00 – Future directions and hopes for expanded CT-132 research

Thanks for listening to the NeurologyLive Mind Moments podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, "Differentiating Dravet and Lennox-Gastaut: Diagnosis, Research, and What’s Ahead," Joyce Lee-Iannotti, MD, PhD, division chief of both the Stroke Center and the Comprehensive Sleep Center at Barrow Neurological Institute, discusses her presentation from the 2025 SLEEP Annual Meeting focused on the glymphatic system’s role in stroke. She outlines the science behind this brain-cleansing pathway, its dependence on sleep quality, and how its dysfunction may worsen outcomes in both ischemic and hemorrhagic stroke. Lee-Iannotti also details practical, evidence-backed strategies for optimizing glymphatic clearance—from sleep posture and sleep apnea treatment to emerging pharmacologic options like orexin antagonists. In addition, she highlights major gaps in clinician awareness and offers calls to action for improving sleep assessments in stroke care.

Episode Breakdown:

1:00 – Overview of the glymphatic system and its relevance in stroke care

2:55 – Evidence linking sleep quality and glymphatic activity in stroke prevention and recovery

7:40 – Neurology News Minute

10:05 – Potential interventions: pharmacologic and nonpharmacologic approaches to enhance glymphatic function

13:10 – Raising clinical awareness of sleep’s role in stroke and neurologic disease management

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, "Differentiating Dravet and Lennox-Gastaut: Diagnosis, Research, and What’s Ahead," Joseph Sullivan, MD, director of the Pediatric Epilepsy Center at UCSF, joins Mind Moments to discuss the clinical distinctions between Dravet syndrome and Lennox-Gastaut syndrome (LGS). Sullivan outlines the unique diagnostic profiles, seizure presentations, and genetic underpinnings of each disorder, while also addressing how genetic testing has transformed the approach to Dravet syndrome in particular. He speaks on the future of targeted therapies, highlighting ongoing research in disease-modifying treatments and n-of-1 trials, especially for ultra-rare epilepsies. Additionally, Sullivan explores how the clinical trial landscape is evolving—emphasizing the need for biomarkers, innovative trial design, and better tools for seizure monitoring to improve outcomes in these complex pediatric epilepsies.

Episode Breakdown:

1:00 – Key differences in phenotype and diagnosis between Dravet syndrome and LGS

3:00– The evolution of genetic testing and how it’s improved Dravet diagnosis and outcomes

5:25 – Opportunities and limitations in scaling genetic testing more broadly

6:35 – Neurology News Minute

8:45 – Research pipelines: disease-modifying therapies, n-of-1 trials, and future directions

10:20 – Innovations in clinical trial design and the need for better seizure monitoring and biomarkers

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, "Bemdaneprocel and the Future of Cell Therapy in Parkinson Disease" Rajesh Pahwa, MD, director of the Parkinson’s Disease and Movement Disorder Center at the University of Kansas Medical Center, discusses the phase 3 exPDite-2 trial evaluating bemdaneprocel, an investigational cell therapy for Parkinson disease (PD). Pahwa explains the rationale behind cell replacement therapy as a means to restore dopamine production, outlining the progression from fetal tissue implants to stem cell–derived dopaminergic neurons. He details key elements of the study design, including patient selection criteria, trial endpoints, and long-term goals. Reflecting on decades of research in this space, he emphasizes the potential impact of a one-time, hardware-free surgical option and how this novel approach could complement or shift the current treatment landscape. While many questions remain, Pahwa highlights the promise of bemdaneprocel as a next-generation option in Parkinson care.

Episode Breakdown:

1:00 – Mechanism and rationale behind bemdaneprocel as a dopaminergic cell therapy

3:00– Key design considerations for conducting a registrational phase 3 cell therapy trial

5:25 – Trial structure, eligibility criteria, and ongoing patient recruitment

6:35 – Neurology News Minute

8:45 – Significance of reaching phase 3 with a cell therapy in Parkinson disease

10:20 – Future role of cell therapy within the Parkinson disease treatment landscape

12:10 – Unique aspects of the exPDite-2 trial and what sets it apart from earlier efforts

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, "World MS Day: Raising Awareness, Evolving Care, and Empowering Patients," Taylor Hess, MD, a multiple sclerosis specialist at the Michigan Institute for Neurological Disorders (MIND), shares insights in recognition of World MS Day. She reflects on the importance of raising global awareness for MS, the need for equitable care, and the evolving focus of research and treatment. Dr. Hess discusses underrecognized symptoms like fatigue and cognitive dysfunction, and emphasizes the value of the upcoming diagnostic criteria update in enabling earlier intervention. She highlights key research priorities—including progressive MS, symptom management, and remyelination—and speaks to the importance of holistic, lifestyle-informed care. Finally, she shares advice for clinicians on how to communicate a new MS diagnosis with empathy, clarity, and empowerment.

Episode Breakdown:

1:00 – Significance of World MS Day and the importance of global MS awareness

2:05– Commonly recognized vs overlooked MS symptoms in patient care

3:10 – Transitioning to updated MS diagnostic criteria and the need for global provider education

4:15 – Neurology News Minute

6:30 – Research priorities: progressive MS, symptom management, and remyelination strategies

7:35 – The role of lifestyle, risk factor control, and holistic care in MS management

8:50 – Communicating MS diagnosis with empathy, support, and resource guidance

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, "Refining TSC Care: Phenotyping, Clustering, and Clinical Impact," Ajay Gupta, MD, director of the Tuberous Sclerosis Program at Cleveland Clinic, discusses recently published research that used unsupervised clustering to group over 900 patients with tuberous sclerosis complex (TSC) into four clinically meaningful phenotypic clusters. He outlines the distinct traits of each cluster—ranging from tumor risk to cognitive impairment—and explains how variant-specific genetic data helped reinforce these categories. Gupta, who also serves as a professor of neurology at the Cleveland Clinic Lerner School of Medicine, also explores the clinical value of these findings for surveillance planning, early intervention, and future therapeutic trials. He emphasizes that while overlap between clusters exists, this approach lays essential groundwork for precision care and more targeted research in TSC.

Episode Breakdown:

1:00 – Study goals and the shift from genotype-to-phenotype toward phenotype-to-genotype mapping

2:40– Overview of the 4 main phenotypic clusters identified in the TSC population

8:05 – Genetic domain associations and their impact on clinical monitoring and treatment

11:50 – Neurology News Minute

14:45 – Understanding overlap between clusters and avoiding overprediction in clinical settings

17:00 – Implications for future surveillance strategies and precision candidate selection in TSC trials

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.

In this episode, "Down Syndrome and Alzheimer’s: Clinical Trials, Equity, and Patient-Centered Progress," Elizabeth Head, PhD, professor in the department of Pathology and Laboratory Medicine at the University of California, Irvine, discussed the evolving intersection of Down syndrome and Alzheimer disease using updates from the Alzheimer Biomarker Consortium – Down Syndrome (ABC-DS). She detailed how outcome assessments have been refined to meet the unique cognitive profiles of individuals with Down syndrome and shared the progress in launching clinical trials that now include this historically excluded population. Head also addressed the challenges in distinguishing developmental delay from early dementia symptoms, the potential role of anti-amyloid therapies, and how non-pharmacological interventions like sleep apnea treatment may contribute to cognitive preservation. She emphasized the importance of equitable research participation, clinician education, and understanding patient priorities—like independence and respect—when supporting individuals with Down syndrome and their families.

Episode Breakdown:

1:00 – Overview of the ABC-DS initiative and the growing inclusion of Down syndrome in Alzheimer research

2:00– Current state of clinical trials and progress in therapeutic development for this population

3:30 – Evolution of outcome assessments tailored for individuals with Down syndrome

5:40 – Challenges in distinguishing Down syndrome traits from signs of early dementia

7:40 – Clinician educations needs and improving access to specialized care

9:00 – Neurology News Minute

11:00 – Eligibility and considerations for anti-amyloid therapies in Down syndrome

13:35 – Research gaps, co-occurring conditions, and the importance of reaching underserved populations

16:40 – Top priorities from patients and families: independence, inclusion, and respect in care settings

The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.